Exome Asset Management
VC Fund
New York, United States
Exome Asset Management is an asset management company focused on investing in public markets across the worldwide healthcare industry, including pharmaceuticals, biopharmaceuticals, healthcare services, medical devices, and more. Their strategy invests broadly across worldwide healthcare sub-sectors and geographies. It employs modest leverage andholds both long and short positions.Exome Asset Management was founded in 2018 and is based in New York, NY, USA.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Exome Asset Management invests in
Stages Exome Asset Management invests in
Countries Exome Asset Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Sam Isaly
|
|||
Investment Focus
Industry
- Biotechnology 7 (88%)
- Health Care 6 (75%)
- Medical 4 (50%)
- Pharmaceutical 4 (50%)
- Big Data 1 (13%)
Stage
- Post-IPO Equity 4 (50%)
- Series D 3 (38%)
- Funding Round 1 (13%)
Country
- China 4 (50%)
- United States 3 (38%)
- Sweden 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sam Isaly
Founder
|
Founder | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NextCure
|
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products. | $21.5M / Post-IPO Equity / Nov 12, 2025 | |
I-Mab Biopharma
|
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. . | $65M / Post-IPO Equity / Aug 01, 2025 | |
Aprea
|
Aprea is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicleowned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB. | $16M / Post-IPO Equity / Mar 11, 2024 | |
Gracell Biotechnologies
|
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives. | $100M / Post-IPO Equity / Aug 07, 2023 | |
IMPACT Therapeutics
|
IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. | Series D / Mar 14, 2022 | |
Broncus Technologies
|
Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatmentof homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population.Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema.Broncus is located in Mountain View, CA (San Francisco Bay area).Broncus International is located in Nyon, Switzerland. | Series D / Jan 28, 2021 | |
Centrexion Therapeutics
|
Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm.We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm. | $40.5M / Oct 29, 2020 | |
New Horizon Health
|
New Horizon Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancerscreening into thousands of households so that the public can enjoy convenient and efficient health services . | $20M / Series D / Apr 21, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Exome Asset Management invest in?
Exome Asset Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series D stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Exome Asset Management?
Public channels for Exome Asset Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Exome Asset Management?
The team at Exome Asset Management includes Sam Isaly (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
